Gonorrhoea - Pipeline Insight, 2024

This “Gonorrhoea - Pipeline Insight, 2024,” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Gonorrhoea pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Gonorrhoea Understanding

Gonorrhoea: Overview

Gonorrhoea is a sexually transmitted infection (STI), usually passed on through unprotected vaginal, anal or oral sex. It is caused by bacteria called Neisseria gonorrhoeae or gonococcus. Gonorrhoea used to be known as the clap. Typical symptoms of gonorrhoea include a thick green or yellow discharge from the vagina or penis, pain when peeing and, in women, bleeding between periods. Testing for gonorrhea is done by swabbing the infected site (rectum, throat, and cervix) and identifying the bacteria in the laboratory. Gonorrhoea is usually treated with a single antibiotic injection or a single antibiotic tablet.

Gonorrhoea - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Gonorrhoea pipeline landscape is provided which includes the disease overview and Gonorrhoea treatment guidelines. The assessment part of the report embraces, in depth Gonorrhoea commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Gonorrhoea collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Gonorrhoea R&D. The therapies under development are focused on novel approaches to treat/improve Gonorrhoea.

Gonorrhoea Emerging Drugs Chapters

This segment of the Gonorrhoea report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Gonorrhoea Emerging Drugs

Gepotidacin: Glaxo SmithKlineGepotidacin (GSK2140944) belongs to class of antibiotics, called triazaacenaphthylene topoisomerase inhibitors. Gepotidacin works by selectively interacting with two key bacterial enzymes, DNA gyrase and topoisomerase IV (type II topoisomerases), responsible for bacterial replication. The novel MOA confers activity against most target pathogens resistant to established antibiotics, including fluoroquinolones. The drug is in Phase III clinical studies for the treatment of uncomplicated urinary tract infection(uUTI)/gonorrhea.

Zoliflodacin: Entasis Therapeutics Zoliflodacin (ETX0914) is an orally bioavailable antibacterial agent. It is a novel spiropyrimidinetrione bacterial DNA gyrase/topoisomerase inhibitor. The drug is in Phase III clinical developmental studies for the treatment of gonorrhoea.

Gonorrhoea: Therapeutic Assessment

This segment of the report provides insights about the different Gonorrhoea drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Gonorrhoea

There are approx. 12+ key companies which are developing the therapies for Gonorrhoea. The companies which have their Gonorrhoea drug candidates in the most advanced stage, i.e. Phase III include, GlaxoSmithKline.

Phases

This report covers around 12+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Gonorrhoea pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Gonorrhoea: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Gonorrhoea therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Gonorrhoea drugs.

Gonorrhoea Report Insights

• Gonorrhoea Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Gonorrhoea Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Gonorrhoea drugs?
• How many Gonorrhoea drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Gonorrhoea?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Gonorrhoea therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Gonorrhoea and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Evofem Biosciences
• GlaxoSmithKline
• Entasis Therapeutics
• Alopexx Pharmaceuticals
• Nobelex Biotech
• Summit Therapeutics
• TherapyX
• AchilleS Vaccines
• Recce Pharmaceuticals
• VenatoRx Pharmaceuticals

Key Products

• EVO 100
• Gepotidacin
• Zoliflodacin
• F 598

Research programme: Enoyl-ACP reductase inhibitors- SMT 571

• GneX 12
• Gonorrhoea vaccine
• RECCE 435
• PBP-539

This product will be delivered within 2 business days.